Will Alaunos Therapeutics stock go up?

According to Danelfin AI, Alaunos Therapeutics has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.54%) is -5.28% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Alaunos Therapeutics stock?

The Alaunos Therapeutics target price is $2.1 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Alaunos Therapeutics stock right now?

Alaunos Therapeutics has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (45.54%) is -5.28% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Alaunos Therapeutics stock is a good buy .

Is Alaunos Therapeutics undervalued right now?

Based on analysts, the average price target downside for Alaunos Therapeutics is 0.00% (1Y). According to Danelfin AI, Alaunos Therapeutics has today an AI Score of 3/10 (Sell Rating).

What was the price range of Alaunos Therapeutics stock over the past 12 months?

The Alaunos Therapeutics stock price range over the past 12 months has been $1.77 - $5.13.

What is going on with Alaunos Therapeutics stock in the last 3 months?

The Alaunos Therapeutics stock performance in the last quarter has been -28.81%.

Does Alaunos Therapeutics offer dividend payments?

No, Alaunos Therapeutics does not currently pay dividends.

What is the current market capitalization of Alaunos Therapeutics?

Alaunos Therapeutics's market cap is $5.08M, as of 2026-07-03 08:00.

Alaunos Therapeutics Inc (TCRT) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

TCRT AI-Powered Stock Analysis

AI Score Explanation

AI Score

Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Alaunos Therapeutics Inc today receives an AI Score of 3/10, which translates to a Sell rating. The stock has a 46% probability of outperforming the market in the next 3 months, which is 5% lower than the average probability of any stock (51%). The top positive contributor is the Chart Pattern (120d), which adds +0.88% to the probability. On the other hand, the top detractors include the Chart Pattern (504d) (-1.61%), the Biotechnology industry (-1.19%), and the Fundamentals Impact (Long Tail) (-0.95%), among others. Notable data points include Institutional Ownership at 5.16% (bottom 20%), Beginning Cash at $1.38M (bottom 10%), and Net PP&E at $0.08M (bottom 10%), all of which weigh negatively. The Fear & Greed Index at 31 (extreme fear) also detracts. On the positive side, Performance (YTD) at -34.98% (bottom 20%) and Alpha 1Y at -75.81% (bottom 20%) surprisingly boost the probability, likely due to mean-reversion expectations. Overall, the stock faces significant headwinds from weak fundamentals and negative technical patterns, resulting in a below-average probability and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+0.27%
Stability and reliability of reported earnings
Profitability+0.27%
Profitability and operating efficiency metrics
Volatility+0.20%
How much the stock price tends to fluctuate

Sentiment-2.86%
How analysts and the market view the stock
Valuation-2.30%
How the stock is priced relative to its fundamentals
Size & Liquidity-0.37%
Company size and trading liquidity
Financial Strength-0.36%
Balance sheet strength and financial resilience
Momentum-0.14%
Direction and strength of recent price movements

TCRT probability advantage of beating the market (3M):

-5.28%

Technical

Alaunos Therapeutics (TCRT) has a Technical Score of 4/10 because, according to only technical analysis, it has a probability advantage of -3.12% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.73%) and the probability of TCRT (47.60%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.73%
TCRT probability advantage of beating the market (only technical, 3M)-3.12%
TCRT probability of beating the market (3M)47.60%

TCRT probability advantage of beating the market (only technical, 3M): -3.12%

The AI-powered technical analysis of Alaunos Therapeutics (TCRT) is only based on the 31 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of TCRT:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	+12.86%
Technical	Upgrade to Pro to unlock	-11.48%
Technical	Upgrade to Pro to unlock	-11.22%
Technical	Upgrade to Pro to unlock	+6.79%
Technical	Upgrade to Pro to unlock	-5.89%
Technical	Upgrade to Pro to unlock	-3.37%
Technical	Upgrade to Pro to unlock	+3.17%
Technical	Upgrade to Pro to unlock	+3.06%
Technical	Upgrade to Pro to unlock	+2.84%
Technical	Upgrade to Pro to unlock	-2.71%
Technical	Upgrade to Pro to unlock	+2.62%
Technical	Upgrade to Pro to unlock	-2.58%
Technical	Upgrade to Pro to unlock	+2.54%
Technical	Upgrade to Pro to unlock	-2.31%
Technical	Upgrade to Pro to unlock	+2.25%

Rest of Alpha Signals: +0.30%

TCRT probability advantage of beating the market (only technical, 3M)Total:-3.12%
TCRT Technical Score

Significant changes Vs previous day

TCRT Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.10
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

TCRT Proven Sell Signal & Price Forecast

This is the price chart for TCRT from January 2, 2026 until today. The chart indicates, in red, the 113 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

TCRT Average Past Performance & Loss Rate

Three months after its 1766 Sell signals since July 2026, TCRT had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

1766 Past TCRT Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-39.13%
Average Alpha				-53.13%
Loss Rate (% Negative Perf.)				83.99%
% Negative Alpha				85.21%

TCRT Frequently Asked Questions

Will Alaunos Therapeutics stock go up?
According to Danelfin AI, Alaunos Therapeutics has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (45.54%) is -5.28% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Alaunos Therapeutics stock?
Is it a good time to buy, sell, or hold Alaunos Therapeutics stock right now?
Is Alaunos Therapeutics undervalued right now?
What was the price range of Alaunos Therapeutics stock over the past 12 months?
What is going on with Alaunos Therapeutics stock in the last 3 months?
Does Alaunos Therapeutics offer dividend payments?
What is the current market capitalization of Alaunos Therapeutics?

Alaunos Therapeutics Inc Company Profile

Alaunos Therapeutics, Inc., with a focus on oncology, stands as a clinical-phase biopharmaceutical entity engaged in the research and development of revolutionary cell therapies. The company, leveraging the potential of adoptive TCR-engineered T-cell therapies, spearheads the advancement of its innovative therapeutic project--TCR Library. Presently undergoing Phase I/II clinical feasibility studies, the TCR Library has been engineered to respond to 12 TCR mutations including KRAS, TP53, and EGFR. Its applications span across a plethora of cancers: non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct. Furthermore, Alaunos has pioneered 'hunTR', an ingenious engine powering human neoantigen T-cell receptors.

An impressive bouquet of licensing agreements form part of Alaunos' strategic initiatives such as with PGEN Therapeutics Inc., and pacts pertaining to research and development with significant entities like The University of Texas MD Anderson Cancer Center and the National Cancer Institute. It's important to note that Alaunos was initially christened ZIOPHARM Oncology Inc., before it adopted its present name in January 2022.

With foundations laid back in 2003, Alaunos operates globally from its nerve center located in Houston; Texas continues to be the birthplace for many revolutionary solutions that make strides towards eradicating cancer.

Sector:
Country:United States
Industry:
Address:501 E Las Olas Blvd, Suite 300, FORT LAUDERDALE
Employees:1
Website:alaunos.com

Pros

Proprietary non-viral TCR gene transfer platform

Addressing high unmet medical need in solid tumors

Broad applicability of TCR-T for intracellular targets

Potential for improved manufacturing scalability

Intellectual property protection for core technology

Cons

High attrition risk in early-stage clinical trials

Intense competition in oncology cell therapy market

Substantial capital requirements for R&D and trials

Complex regulatory pathway for novel cell therapies

Logistical challenges of autologous cell therapy manufacturing

TCRT Stock AI Analysis